FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220980350> ?p ?o ?g. }

• W4220980350 abstract "Abstract Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an antibody response after COVID infection. There is limited data on the efficacy of the COVID vaccines in lymphoma patients, and to suggest the optimal timing of vaccination to elicit immunity in patients receiving immunochemotherapy. This is a retrospective study of adult lymphoma patients who received the COVID vaccine between 12/1/2020 and 11/30/2021. The primary endpoint was a positive anti-COVID spike protein antibody titer following the primary COVID vaccination series. The primary series was defined as 2 doses of the COVID mRNA vaccines or 1 dose of the COVID adenovirus vaccine. Subgroups were compared using Fisher’s exact test, and unadjusted and adjusted logistic regression models were used for univariate (UVA) and multivariate (MVA) analyses. A total of 243 patients were included in this study; 72 patients (30%) with indolent lymphomas; 56 patients (23%) with Burkitt’s, diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma (PMBL) combined; 55 patients (22%) with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL); and 44 patients (18%) with Hodgkin and T-cell lymphomas (HL/TCL) combined. One-hundred fifty-eight patients (65%) developed anti-COVID spike protein antibodies after completing the primary COVID vaccination series. Thirty-eight of 46 (83%) patients who received an additional primary shot and had resultant levels produced anti-COVID spike protein antibodies. When compared to other lymphoma types, patients with CLL/SLL had a numerically lower seroconversion rate of 51% following the primary series whereas patients with HL/TCL appeared to have a robust antibody response with a seropositivity rate of 77% (p=0.04). Lymphoma patients are capable of mounting a humoral response to the COVID mRNA vaccines. Further studies are required to confirm our findings, including whether T-cell immunity would be of clinical relevance in this patient population." @default.
• W4220980350 created "2022-04-03" @default.
• W4220980350 creator A5002235860 @default.
• W4220980350 creator A5006524635 @default.
• W4220980350 creator A5008419917 @default.
• W4220980350 creator A5010848046 @default.
• W4220980350 creator A5012233625 @default.
• W4220980350 creator A5013717203 @default.
• W4220980350 creator A5021466990 @default.
• W4220980350 creator A5022685626 @default.
• W4220980350 creator A5025036628 @default.
• W4220980350 creator A5041247024 @default.
• W4220980350 creator A5050845011 @default.
• W4220980350 creator A5060681637 @default.
• W4220980350 creator A5071416138 @default.
• W4220980350 creator A5075752482 @default.
• W4220980350 creator A5083767894 @default.
• W4220980350 creator A5089882481 @default.
• W4220980350 creator A5090941234 @default.
• W4220980350 date "2022-03-24" @default.
• W4220980350 modified "2023-09-26" @default.
• W4220980350 title "Production of anti-spike antibodies in response to COVID vaccine in lymphoma patients" @default.
• W4220980350 cites W2020206181 @default.
• W4220980350 cites W2625522638 @default.
• W4220980350 cites W2961584252 @default.
• W4220980350 cites W3159638076 @default.
• W4220980350 cites W3159689317 @default.
• W4220980350 cites W3173185194 @default.
• W4220980350 cites W3182590535 @default.
• W4220980350 cites W3184620427 @default.
• W4220980350 cites W3199514102 @default.
• W4220980350 doi "https://doi.org/10.1101/2022.03.24.22272883" @default.
• W4220980350 hasPublicationYear "2022" @default.
• W4220980350 type Work @default.
• W4220980350 citedByCount "2" @default.
• W4220980350 countsByYear W42209803502022 @default.
• W4220980350 countsByYear W42209803502023 @default.
• W4220980350 crossrefType "posted-content" @default.
• W4220980350 hasAuthorship W4220980350A5002235860 @default.
• W4220980350 hasAuthorship W4220980350A5006524635 @default.
• W4220980350 hasAuthorship W4220980350A5008419917 @default.
• W4220980350 hasAuthorship W4220980350A5010848046 @default.
• W4220980350 hasAuthorship W4220980350A5012233625 @default.
• W4220980350 hasAuthorship W4220980350A5013717203 @default.
• W4220980350 hasAuthorship W4220980350A5021466990 @default.
• W4220980350 hasAuthorship W4220980350A5022685626 @default.
• W4220980350 hasAuthorship W4220980350A5025036628 @default.
• W4220980350 hasAuthorship W4220980350A5041247024 @default.
• W4220980350 hasAuthorship W4220980350A5050845011 @default.
• W4220980350 hasAuthorship W4220980350A5060681637 @default.
• W4220980350 hasAuthorship W4220980350A5071416138 @default.
• W4220980350 hasAuthorship W4220980350A5075752482 @default.
• W4220980350 hasAuthorship W4220980350A5083767894 @default.
• W4220980350 hasAuthorship W4220980350A5089882481 @default.
• W4220980350 hasAuthorship W4220980350A5090941234 @default.
• W4220980350 hasBestOaLocation W42209803501 @default.
• W4220980350 hasConcept C126322002 @default.
• W4220980350 hasConcept C159047783 @default.
• W4220980350 hasConcept C159654299 @default.
• W4220980350 hasConcept C203014093 @default.
• W4220980350 hasConcept C22070199 @default.
• W4220980350 hasConcept C2777451964 @default.
• W4220980350 hasConcept C2778190748 @default.
• W4220980350 hasConcept C2779338263 @default.
• W4220980350 hasConcept C71924100 @default.
• W4220980350 hasConceptScore W4220980350C126322002 @default.
• W4220980350 hasConceptScore W4220980350C159047783 @default.
• W4220980350 hasConceptScore W4220980350C159654299 @default.
• W4220980350 hasConceptScore W4220980350C203014093 @default.
• W4220980350 hasConceptScore W4220980350C22070199 @default.
• W4220980350 hasConceptScore W4220980350C2777451964 @default.
• W4220980350 hasConceptScore W4220980350C2778190748 @default.
• W4220980350 hasConceptScore W4220980350C2779338263 @default.
• W4220980350 hasConceptScore W4220980350C71924100 @default.
• W4220980350 hasLocation W42209803501 @default.
• W4220980350 hasOpenAccess W4220980350 @default.
• W4220980350 hasPrimaryLocation W42209803501 @default.
• W4220980350 hasRelatedWork W1629091285 @default.
• W4220980350 hasRelatedWork W2043803693 @default.
• W4220980350 hasRelatedWork W2079952684 @default.
• W4220980350 hasRelatedWork W2080273809 @default.
• W4220980350 hasRelatedWork W2131146007 @default.
• W4220980350 hasRelatedWork W3127359265 @default.
• W4220980350 hasRelatedWork W3128830683 @default.
• W4220980350 hasRelatedWork W3138104571 @default.
• W4220980350 hasRelatedWork W4205620208 @default.
• W4220980350 hasRelatedWork W4210269439 @default.
• W4220980350 isParatext "false" @default.
• W4220980350 isRetracted "false" @default.
• W4220980350 workType "article" @default.